Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

About this update from Boundless Bio, Inc.

[{"type":"image","alt":"Boundless Bio, Inc.","displaySize":"","headline":null,"caption":"Boundless Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/445cbf87d86da6c7106a163824081ecf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FRxtD5.d3Ya65U8g2X8nWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/445cbf87d86da6c7106a163824081ecf","width":255,"height":38}},"lazy":false},{"type":"text","content":"Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025","length":164,"tagName":"p"},{"type":"text","content":"Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026","length":117,"tagName":"p"},{"type":"text","content":"$138 million cash position provides operating runway into 2027 ","length":62,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2025.","length":365,"tagName":"p"},{"type":"text","content":"“Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio. “We look forward to providing a clinical data update on our BBI-355 program later this year. Additionally, we expect to nominate a development candidate for our novel Kinesin program by mid-year, with plans to submit an IND in the first half of 2026."","length":442,"tagName":"p"},{"type":"text","content":"Research and Development Highlights and Upcoming Milestones","length":59,"tagName":"p"},{"type":"text","content":"BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers","length":113,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment is ongoing in the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept sa...

More updates from Boundless Bio, Inc.